Danielle Brandman, MD
Transplant Hepatology · San Francisco, CANPI 1518164540
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,590 of the $7,232 with a category attached, or 91.1%. 5 manufacturers reported payments, led by Madrigal Pharmaceuticals at 56.4% of the total. 2025 is the largest year on record at $4,105, more than ten times the $139 reported in 2022.
Across 14 payments — averaging $516.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Madrigal Pharmaceuticals$4K
- Novo Nordisk$3K
- Gilead$212
- Boston Scientific$135
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$93
Across 44 payments — averaging $7794.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$205K
- AbbVie$82K
- Gilead$40K
- Grifols Therapeutics LLC$16K
What the payments were for
- Consulting fees$6,59091%
- Food & beverage$6429%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Madrigal Pharmaceuticals | 4 | $4,080 |
| Novo Nordisk | 1 | $2,713 |
| Gilead | 3 | $212 |
| Boston Scientific | 3 | $135 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $93 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,232 in reported general payments places this provider in the 65th percentile of 39 transplant hepatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other transplant hepatology in San Francisco
- Jennifer LaiSan Francisco$70K
- Kidist YimamSan Francisco$53K
- Bilal HameedSan Francisco$44K
- Jennifer PriceSan Francisco$11K
- Chanda HoSan Francisco$3K
- Edward HoltSan Francisco$3K
- Jin GeSan Francisco$2K
- Jennifer GuySan Francisco$245
- Raphael MerrimanSan Francisco$217
- Adil WakilSan Francisco$96
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.